Vermillion Wealth Management’s TG Therapeutics TGTX Stock Holding History

Vermillion Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.5K	Hold	500	–	–	0.01%	802
2026 Q1	$16.6K	Sell	500 -500	-50%	-$14.9K	0.01%	324
2025 Q4	$29.8K	Hold	1,000	–	–	0.01%	245
2025 Q3	$36.1K	Hold	1,000	–	–	0.01%	672
2025 Q2	$36K	Hold	1,000	–	–	0.02%	207
2025 Q1	$39.4K	Hold	1,000	–	–	0.01%	561
2024 Q4	$30.1K	Buy	+1,000	New	+$28.7K	0.02%	224

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vermillion Wealth Management's TGTX Position: Q2 2026 in Review

Vermillion Wealth Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 500 shares worth $27.5K. The position accounts for 0.01% of the portfolio, ranked #802.

Vermillion Wealth Management first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $39.4K in Q1 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Vermillion Wealth Management held 500 shares of TG Therapeutics worth $27.5K as of Q2 2026.
Vermillion Wealth Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.01% of Vermillion Wealth Management's portfolio in Q2 2026, its #802 holding.
Vermillion Wealth Management first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
Vermillion Wealth Management's TG Therapeutics position peaked at $39.4K in Q1 2025.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.